Document is current
Any future updates will be listed below
-
Authors
Willmann, Matthias https://orcid.org/0000-0003-0095-4640
Vehreschild, Maria J. G. T.
Biehl, Lena M.
Vogel, Wichard
Dörfel, Daniela
Hamprecht, Axel
Seifert, Harald
Autenrieth, Ingo B.
Peter, Silke
-
Funding
Funding for this research was provided by:
German Center for Infection Research (TTU 08.802)
- License Information
-
More Information
Article History
Received: 20 May 2019
Accepted: 27 August 2019
First Online: 18 September 2019
Ethics approval and consent to participate
: The local ethics committees approved the study (reference numbers: 661/2013BO1 and 14-021, respectively). All patients provided written consent before participating in the study. Data monitoring of patient data was performed at both centers. The study has been registered at with the identifier NCT02058888.
: Not applicable.
: MJGTV is a consultant to Alb Fils Kliniken GmbH, Berlin Chemie, MSD/Merck, and Astellas Pharma; has served at the speakers’ bureau of Astellas Pharma, Basilea, Gilead Sciences, Merck/MSD, Organobalance, and Pfizer; received research funding from 3M, Astellas Pharma, DaVolterra, Gilead Sciences, Merck/MSD, Morphochem, Organobalance, and Seres Therapeutics.The other authors declare that they have no competing interests.
